LARIAGO (Chloroquine (40mg))

Lariago 50mg Suspension is an anti-parasitic medication utilized primarily for the prevention and treatment of malaria, which is transmitted through mosquito bites. This medication can also be effective in addressing intestinal infections in pediatric patients caused by certain parasites, specifically amoebas. It is important to administer Lariago 50mg Suspension orally to children, preferably after meals, to minimize the risk of gastrointestinal discomfort. Care should be taken to avoid giving antacids during the four hours surrounding the administration of this medication, as they may hinder the absorption process. The suspension may have a slightly bitter taste, so mixing it with fruit juice can help to mitigate this. If a child vomits shortly after taking the medication, it is advisable to allow them to calm down before administering the same dose again after a 30-minute interval. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped, and the dosing schedule should not be doubled. The dosage and timing prescribed by the healthcare provider should be strictly adhered to, based on factors such as the child’s weight, age, clinical status, and response to treatment. Initial treatment may involve higher doses for the first couple of days, followed by a gradual reduction. Prolonged use of Lariago 50mg Suspension requires careful monitoring due to the potential for serious adverse effects in pediatric patients. It is crucial to inform the physician of the child’s complete medical history, including any allergies and current medications, as well as any past health issues related to the liver, kidneys, heart, brain, or hereditary conditions. This information is vital for devising an effective treatment plan.